Karlijn Wilschut Promega Discover Glo March 10, 2015-‐ AMC Amsterdam

22 Pages·2015·10.04 MB·English

Karlijn
 Wilschut

Promega
 Discover
 Glo

March
 10,
 2015-­‐
 AMC
 Amsterdam
Early
 a’ri)on

Dr
u
g
di
s
c
o
v
er
y

n
e Clinical trials
e y al FDA
cr arn c 1
s de ni e
y onre cli as Phase 2 Phase 3
ar cc e h
m es r P
S P 1.5 years
i 7 years
r
P
6 . 5 y e a r s
1 FDA
10,000 250
5 compounds
approved drug
compounds compounds
$ 0.8~1.8 bn
Early
 a’ri)on

Dr
u
g
di
s
c
o
v
er
y

n
e Clinical trials FDA
e y l
a
cr arn c
s de ni
y onre cli Phase 1 Phase 2 Phase 3
ar cc e
m es r
S P
i
r
P
6 . 5 y e a r s
In
 need
 of
 be’er
 predic)ve
 models

2D
 culture 3D
 culture

2D
 culture

Animal
 tesCng

  Human
 Cssues

Layered
 co-­‐culture

Tube
 formaCon

Boundary
 Cssues

OrganoPlate™
™

OrganoPlates
PhaseGuides

⊃  Fully
 passive
 liquid
 control

⊃  Easy
 filling
 of
 any
 shape

⊃  Liquid
 &
 gel
 paSerning

⊃  Gradient
 formaCon

⊃  Organ
 and
 Cssue
  ⊃  Tissue
 layering

funcConality

⊃  Perfusion

⊃  High
 throughput

⊃  Low
 reagent

consumpCon

⊃  CompaCble
 format
Movie:
 hSp://youtu.be/L_VEJAZ5J6U
OrganoPlateTM

Gel+ cells
Medium + compound
Gel
Gel
Medium + cells
90° rotation
Gel
Gel
MIMETAS
 OrganoPlate™
 96x

2-­‐lane
 chip:
 gel
 lane
 (red)
 and

Basal Apical
perfusion
 lane
 (blue)

z
y
Flow/
 perfusion

Flow
 created
 by
 perfusion-­‐by-­‐levelling

Perfusion-­‐by-­‐levelling
 on
 a
 rocker

plaEorm
Tissue
 model
 designs

2
 -­‐
 lane

3
 -­‐
 lane
Design
 flexibility

…and
 4
 and
 5-­‐lane
 setups